Immix Biopharma (NASDAQ:IMMX) Trading 7.1% Higher – What’s Next?

Immix Biopharma, Inc. (NASDAQ:IMMX)’s stock price shot up 7.1% during mid-day trading on Tuesday . The stock traded as high as $10.67 and last traded at $10.8450. Approximately 821,072 shares traded hands during trading, a decline of 34% from the average session volume of 1,238,697 shares. The stock had previously closed at $10.13.

Immix Biopharma News Roundup

Here are the key news stories impacting Immix Biopharma this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $25 price target, more than double the recent trading level. The analyst projects improving results through fiscal 2027, including a return to positive EPS of $0.31 in the fourth quarter of 2027. HC Wainwright Comments on Immix Biopharma FY2027 Earnings
• Positive Sentiment: A separate report highlighted Immix Biopharma among healthcare stocks viewed favorably by analysts, reinforcing the constructive outlook surrounding the company’s pipeline and longer-term growth prospects. Analysts Are Bullish on These Healthcare Stocks
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day short-interest ratio. However, the data appears inconsistent or unavailable, so it provides little useful information about current investor positioning.
• Negative Sentiment: HC Wainwright lowered its projected EPS losses for the third quarter and full year 2026 to $0.17 and $0.72, respectively, from prior estimates of $0.14 and $0.62. The Q4 2026 loss estimate was also widened to $0.19 from $0.15, indicating greater near-term cash-burn or execution concerns despite the unchanged Buy rating.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Immix Biopharma investors. The announcement does not establish wrongdoing, but securities investigations can create headline risk and weigh on sentiment.

Wall Street Analysts Forecast Growth

IMMX has been the topic of several recent research reports. Bank of America assumed coverage on Immix Biopharma in a report on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective on the stock. Needham & Company LLC initiated coverage on Immix Biopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price for the company. Morgan Stanley dropped their target price on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday. Lifesci Capital began coverage on Immix Biopharma in a research note on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.29.

Immix Biopharma Trading Up 0.4%

The company’s 50-day simple moving average is $9.52 and its 200-day simple moving average is $8.98. The stock has a market capitalization of $621.31 million, a price-to-earnings ratio of -12.91 and a beta of 0.11.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, equities research analysts expect that Immix Biopharma, Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Allworth Financial LP bought a new stake in shares of Immix Biopharma in the 4th quarter valued at about $30,000. Mathes Company Inc. acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at about $56,000. Compass Financial Management LLC bought a new position in shares of Immix Biopharma during the second quarter worth about $56,000. Balyasny Asset Management L.P. bought a new position in shares of Immix Biopharma during the fourth quarter worth about $67,000. Finally, Kera Capital Partners Inc. acquired a new position in shares of Immix Biopharma in the fourth quarter worth approximately $68,000. 11.26% of the stock is owned by institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.